Mild Cognitive Impairment - Market Insight, Epidemiology And Market Forecast - 2034
Key Highlights:
- In 2023, the market size of Mild Cognitive Impairment (MCI) was highest in the US among the 7MM, accounting for approximately USD 1,467 million which is further expected to increase by 2034.
- In 2023, the total diagnosed prevalence of MCI in Parkinson's disease was highest in Germany among the EU4 and the UK, accounting for nearly 223 thousand cases which is further expected to increase by 2034.
- In the US, in 2023, ~6,978 thousand people were affected with Alzheimer disease, accounting for the highest number of cases in the 7MM. DelveInsight estimates that these numbers will increase by 2034.
- In 2023, among the 7MM, the US accounted for the highest prevalent cases of MCI, representing 42% of the total cases, followed by Japan (27%), Germany (10%), and France (7%). Analysis by DelveInsight's experts indicates that the overall diagnosed prevalent cases of MCI are expected to rise in the coming years.
- The current market of MCI includes approved therapies such as LEQEMBI (lecanemab), along with off-label therapies like cholinesterase inhibitors, memantine, and others, contributing to a market size of USD 222 million in the 7MM in 2023. The market size is expected to increase with the projected launch of emerging therapies during the forecast period (2024-2034).
- In July 2024, the US FDA approved KISUNLA (donanemab-azbt, 350 mg/20 mL), an Alzheimer's therapy developed by Eli Lilly for adults with early symptomatic Alzheimer's disease, including MCI and mild dementia with confirmed amyloid pathology.
- The market size of MCI in Japan was nearly USD 670 million in 2023, accounting for 24% of the total market of the 7MM, which is expected to rise by 2034.
DelveInsight's "Mild Cognitive Impairment (MCI) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the MCI, historical and forecasted epidemiology as well as the MCI market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
The Mild Cognitive Impairment (MCI) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM MCI market size from 2020 to 2034. The Report also covers current MCI treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Geography Covered:
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2020-2034
Disease Understanding and Treatment Algorithm
Mild Cognitive Impairment (MCI) Overview
Mild Cognitive Impairment (MCI) is a transitional stage between normal cognitive aging and dementia, characterized by noticeable cognitive decline that does not yet interfere significantly with daily functioning. Individuals with MCI experience memory issues, attention deficits, and impaired judgment, making them more vulnerable to progressing into Alzheimer's disease or other dementias.
MCI's growing prevalence, especially among aging populations, emphasizes the need for early detection and effective management strategies.
Mild Cognitive Impairment (MCI) Diagnosis
Diagnosing MCI involves a comprehensive cognitive assessment, often including memory tests, attention evaluations, and other cognitive performance measures. Neurological exams, imaging, and biomarker analyses further confirm the condition and rule out other causes. Early diagnosis is essential, as it allows clinicians to monitor cognitive progression, assess the risk of developing dementia, and implement supportive interventions to help maintain cognitive function.
Despite advancements in MCI diagnosis, significant unmet needs persist. Challenges due to the subtlety of early symptoms, which often overlap with normal aging or other neurological conditions. Cognitive testing alone may not capture MCI's nuanced presentation, and even with imaging or biomarkers, distinguishing MCI from early-stage dementia remains difficult. Variability in symptoms and progression further complicates diagnosis, often delaying intervention. Additionally, a lack of standardized diagnostic criteria across medical practices limits consistency, making early and accurate identification challenging.
Mild Cognitive Impairment (MCI) Treatment
Currently, MCI treatment focuses on slowing cognitive decline and supporting overall brain health, with therapies such as LEQEMBI and KISUNLA showing promise. Additionally, off-label treatments like cholinesterase inhibitors and memantine, often used in Alzheimer's, are considered to help with MCI symptoms. Non-pharmacological interventions, including cognitive training, lifestyle changes, and regular exercise, complement medical therapies, creating a comprehensive approach to managing MCI.
Treatment of MCI is equally complex, as no approved therapies exist specifically for MCI, and available off-label treatments yield variable results. Pharmacological options, such as cholinesterase inhibitors and memantine, are not universally effective, and their benefits remain uncertain in MCI cases.
Furthermore, non-pharmacological interventions, though beneficial, require sustained lifestyle adjustments that may be challenging for patients to maintain. With MCI's unpredictable progression toward dementia, creating personalized treatment plans that effectively slow cognitive decline remains an ongoing challenge for clinicians.
Mild Cognitive Impairment (MCI) Epidemiology
As the market is derived using a patient-based model, the MCI epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of Parkinson's Disease, Total Diagnosed Prevalent Cases of Alzheimer's Disease, and Total Diagnosed Prevalent Cases of MCI in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
- In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Parkinson's disease in the US were nearly 1,211 thousand in 2023.
- Among European countries, Germany had the highest diagnosed prevalent cases of Alzheimer's disease with ~1,491 thousand cases, followed by France, which had diagnosed prevalent population of ~1,170 thousand in 2023. On the other hand, the UK had the lowest prevalent population (620 thousand cases).
- In Japan, approximately 2,730 thousand diagnosed cases of MCI were identified, with around 103 thousand cases attributed to MCI due to Parkinson's disease and 2,627 thousand cases due to Alzheimer's. Projections suggest that by 2034, the prevalence of Alzheimer's-related MCI will continue to grow and exceed that of Parkinson's-related MCI, highlighting a trend that underscores the increasing impact of Alzheimer's on the aging population.
- DelveInsight's analysis shows that, among the 7MM, the US accounted highest for the total diagnosed prevalent cases of MCI. There were nearly 4,222 thousand diagnosed prevalent cases of MCI in the US in 2023.Projections indicate that the UK is expected to continue leading in these figures by 2034.
Mild Cognitive Impairment (MCI) Drug Chapters
The drug chapter segment of the MCI report encloses a detailed analysis of MCI off-label drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the MCI clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Marketed Drugs
LEQEMBI (lecanemab): Biogen Inc./Eisai Co., Ltd.
LEQEMBI, an FDA-approved treatment for Alzheimer's, specifically targets patients in the MCI or mild dementia stages. Developed as a humanized IgG1 monoclonal antibody, LEQEMBI addresses amyloid B (AB) pathology by reducing both soluble and insoluble forms of AB to slow disease progression.
With ongoing prescription expansion, the focus includes customized facility information on the drug, reimbursement support, and system efficiency enhancements. Approved by regulatory bodies in Great Britain (August 2024) and Japan (September 2023), LEQEMBI marks a significant milestone as the first approved therapy in Europe to target an Alzheimer's-related pathology directly.
KISUNLA (Donanemab): Eli Lilly and Company
KISUNLA (donanemab-azbt), developed by Eli Lilly, targets amyloid plaques in patients with MCI or early symptomatic Alzheimer's disease confirmed by amyloid pathology. This humanized IgG1 monoclonal antibody addresses amyloid B accumulation-a key contributor to Alzheimer's by focusing on insoluble N-truncated pyroglutamate amyloid beta plaques.
Administered intravenously every four weeks, KISUNLA's structured dosing regimen was informed by Phase III TRAILBLAZER-ALZ 2 trial data, supporting approvals in the US (July 2024) and Japan (September 2024). Unique to KISUNLA is the potential to halt treatment once plaques clear, which may optimize efficacy and lower treatment costs.
Emerging Drugs
Valiltramiprosate (ALZ-801): Alzheon Inc.
ALZ-801 (valiltramiprosate) is an oral, small-molecule drug designed to fully inhibit the formation of neurotoxic amyloid oligomers linked to Alzheimer's disease progression. As a valine-conjugated prodrug of tramiprosate, ALZ-801 is converted in vivo to homotaurine, enhancing absorption and extending plasma stability compared to tramiprosate. Both ALZ-801 and tramiprosate are metabolized into 3-sulfopropanoic acid (3-SPA), a naturally occurring brain substance that impedes AB42 aggregation. ALZ-801's improved pharmacokinetic profile minimizes gastrointestinal issues and maintains consistent blood levels, with Phase I data supporting its tolerability. Now in Phase III, ALZ-801 is investigated as a disease-modifying therapy for mild cognitive impairment (MCI).
In October 2017, the US FDA granted Fast Track Designation (FTD) to its lead clinical investigational drug, ALZ-801, to treat Alzheimer's disease.
Mirodenafil (AR1001): AriBio Co., Ltd.
AR1001 is an orally administered, blood-brain barrier-penetrating small molecule with a polypharmacological profile targeting neurodegenerative diseases. It works primarily by selectively inhibiting phosphodiesterase 5 (PDE5), aiming to treat conditions such as Alzheimer's disease, vascular dementia, and Lewy body dementia.
Following promising Phase II results for mild-to-moderate Alzheimer's in the US, AriBio is advancing AR1001 into Phase III trials for early Alzheimer's, targeting patients with mild cognitive impairment (MCI) and mild dementia. Phase III trials are set in the US and Europe. In June 2024, AriBio partnered with Kentucky Clinical Trial Laboratory (KCTL) for Alzheimer's diagnostics, utilizing FujireBio's Lumipulse system.
In April 2024, AirBio received EMA Phase III clinical trial authorization for AR1001 in the treatment of Alzheimer's disease (POLARIS-AD).
Hydromethylthionine Mesylate (HMTM)/TRx0237: TauRx Therapeutics
TauRx Therapeutics' TRx0237, also known as Hydromethylthionine Mesylate (HMTM), is an orally active second-generation Tau protein Aggregation Inhibitor (TAI) targeting tau protein aggregation, which is associated with neurofibrillary tangles in Alzheimer's disease and other neurodegenerative disorders. Tau tangles are implicated in dementia as they form from misfolded tau proteins, leading to neuronal death. TRx0237 is a stabilized, reduced version of methylthioninium chloride (MTC), enhancing absorption, bioavailability, and tolerability.
The drug has successfully completed three Phase III trials-two focused on Alzheimer's disease and one on behavioral variant frontotemporal dementia (bvFTD).
Additionally, in July 2024, Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed acceptance of the UK Marketing Authorisation Application (MAA) for HMTM, a 4 mg oral tablet for the treatment of mild cognitive impairment (MCI-AD) and mild to moderate Alzheimer's disease.
This application is being reviewed within the scope of the 150-day accelerated assessment procedure, which MHRA uses to accelerate the availability of medicines for patients in the UK.
Mild Cognitive Impairment (MCI) Market Outlook
MCI presents as cognitive decline that exceeds typical age-related changes but does not significantly disrupt daily living. Its progression to dementia, particularly Alzheimer's disease, underscores the importance of early detection and intervention. Treatment strategies focus on modifiable risk factors, such as dietary habits, hypertension, and physical activity. While pharmacological options like cholinesterase inhibitors (ChEIs) and memantine may be employed in Alzheimer's-related cases, non-pharmacological interventions including cognitive training, exercise, and lifestyle changes are vital for managing MCI.
The absence of a standardized treatment necessitates personalized management approaches, particularly in patients with comorbid conditions. Although ChEIs are frequently prescribed for Alzheimer's, their efficacy in MCI remains unproven, leading to potential deprescribing recommendations. Established treatments like donepezil, rivastigmine, and galantamine show modest and temporary benefits, while memantine proves effective in moderate to severe cases.
With a growing focus on advanced treatment options, the market for MCI is expanding, highlighting opportunities for innovation and investment in new therapies and technologies.
The MCI market is poised for transformation with the anticipated introduction of therapies like Valiltramiprosate, Mirodenafil, Hydromethylthionine mesylate (HMTM), and others. The approval of these therapies could significantly impact market dynamics, although their success rates remain uncertain.
- The market size of MCI in the 7MM was ~USD 2,836 million in 2023, which is further anticipated to increase during the forecast period.
- The United States accounted for the highest market size of MCI approximately 52% of the total market size in 7MM in 2023, in comparison to the other major markets i.e., EU4 countries (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
- Among the EU countries, Germany had the highest market size with USD 222 million in 2023, while the UK had the lowest market size for MCI with USD ~88 million in 2023.
- The market size for MCI in Japan was estimated to be about USD 670 million in 2023.
- With the expected launch of upcoming therapies, such as Valiltramiprosate, Mirodenafil, and Hydromethylthionine mesylate (HMTM), among others, the total market size of MCI is expected to show change in the upcoming years.
Mild Cognitive Impairment (MCI) Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, Valiltramiprosate in the US is expected to be launched by 2025 with a peak share of 1.0%. Mirodenafil is anticipated to take 7 years to peak with a slow medium uptake.
Mild Cognitive Impairment (MCI) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for MCI emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on MCI evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Boston University School of Public Health, Department of Epidemiology, US, Department of Psychiatry and Human Behavior, Brown University Warren Alpert Medical School, Providence, Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain,vNew York US, Psychiatric Practice Bohlken, Berlin, Germany, Department of Biology, E'cole Normale Supe'rieure de Lyon, Lyon, France, Geriatric, Local Health Authority, Pistoia Italy, Department of Psychiatry, Universidad Autonoma de Madrid, Madrid, Spain, and Department of Occupational Therapy, Graduate School of Medicine, Akita University, Japan.
Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or MCI market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report:
- The report covers a segment of key events, an executive summary, descriptive overview of MCI, explaining its causes, signs and symptoms, and currently available therapies.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
- Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
- A detailed review of the MCI market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM MCI market.
MCI Report Insights
- Patient Population
- Therapeutic Approaches
- Mild Cognitive Impairment (MCI) Pipeline Analysis
- Mild Cognitive Impairment (MCI) Market Size and Trends
- Existing and Future Market Opportunity
Mild Cognitive Impairment (MCI) Report Key Strengths
- 11 years Forecast
- The 7MM Coverage
- Mild Cognitive Impairment (MCI) Epidemiology Segmentation
- Key Cross Competition
- Conjoint Analysis
- Drugs Uptake and Key Market Forecast Assumptions
Mild Cognitive Impairment (MCI) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
Key Questions:
Market Insights
- What was the Mild Cognitive Impairment (MCI) market share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Mild Cognitive Impairment (MCI) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Mild Cognitive Impairment (MCI) market size during the forecast period (2024-2034)?
- At what CAGR, the Mild Cognitive Impairment (MCI) market is expected to grow at the 7MM level during the forecast period (2024-2034)?
- What would be the Mild Cognitive Impairment (MCI) market outlook across the 7MM during the forecast period (2024-2034)?
- What would be the Mild Cognitive Impairment (MCI) market growth till 2034 and what will be the resultant market size in the year 2034?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights
- What is the disease risk, burden, and unmet needs of Mild Cognitive Impairment (MCI)?
- What is the historical Mild Cognitive Impairment (MCI) patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient population of MCI at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Mild Cognitive Impairment (MCI)?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Mild Cognitive Impairment (MCI) during the forecast period (2024-2034)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2024-2034)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current options for the treatment of Mild Cognitive Impairment (MCI) along with the approved therapy?
- What are the current treatment guidelines for the treatment of Mild Cognitive Impairment (MCI) in the US, Europe, And Japan?
- What are the Mild Cognitive Impairment (MCI) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Mild Cognitive Impairment (MCI)?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Mild Cognitive Impairment (MCI)?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Mild Cognitive Impairment (MCI) therapies?
- What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Mild Cognitive Impairment (MCI) and their status?
- What are the key designations that have been granted for the emerging therapies for Mild Cognitive Impairment (MCI)?
- What are the 7MM historical and forecasted market of Mild Cognitive Impairment (MCI)?
Reasons to Buy:
- The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Mild Cognitive Impairment (MCI) Market.
- Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Detailed analysis and potential of current and emerging therapies under the conjoint analysis section to provide visibility around leading emerging drugs.
- Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
- To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future.
- Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.
Frequently Asked Questions:
1. What is the forecast period covered in the report?
The Mild Cognitive Impairment (MCI) Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.
2. Who are the key players in the Mild Cognitive Impairment (MCI) market?
The Mild Cognitive Impairment (MCI) market is quite robust. The major layers are Alzheon Inc., AriBio Co., Ltd., TauRx Therapeutics Ltd, and others which are currently developing drugs for the treatment of MCI.
3. How is the market size estimated in the forecast report?
The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as prevalent cases, treatment costs, revenue generated, and market trends.
4. What is the key driver of the Mild Cognitive Impairment (MCI) market?
The increase in diagnosed prevalent cases of Mild Cognitive Impairment (MCI) and the launch of emerging therapies are attributed to be the key drivers for increasing the MCI market.
5. What is the expected impact of emerging therapies or advancements in Mild Cognitive Impairment (MCI) treatment on the market?
Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the MCI treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.
6. Does the report provide insights into the competitive landscape of the market?
The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Mild Cognitive Impairment (MCI) market.
Table of Contents
1. Key Insights
2. Report Introduction
3. Mild Cognitive Impairment (MCI) Market Overview at a Glance
- 3.1. Market Share (%) Distribution of Mild Cognitive Impairment (MCI) in 2020
- 3.2. Market Share (%) Distribution of Mild Cognitive Impairment (MCI) in 2034
4. Methodology of Mild Cognitive Impairment (MCI) Epidemiology and Market
5. Executive Summary
6. Key Events
7. Disease Background and Overview
- 7.1. Introduction to Mild Cognitive Impairment (MCI)
- 7.2. Classification of MCI
- 7.3. Signs and Symptoms
- 7.4. Risk Factors
- 7.5. Pathophysiology
- 7.6. Diagnosis
- 7.6.1. Diagnostic Algorithm
- 7.6.2. Diagnostic Guidelines
- 7.6.2.1. Practice Guideline Update Summary: MCI by American Academy of Neurology
- 7.6.2.2. MCI: The Manchester Consensus
- 7.6.2.3. German Society of Neurology Guidelines for the Diagnosis and Treatment of Cognitive Impairment and Affective Disorders in People with Parkinson's Disease: New Spotlights on Diagnostic Procedures and Non-Pharmacological Interventions
- 7.6.2.4. The Italian Guideline "Diagnosis and treatment of Dementia and MCI"
- 7.6.2.5. The Japanese MCI Screen for Early Detection of Alzheimer's Disease and Related Disorders
- 7.7. Treatment and Management
- 7.7.1.1. Pharmacologic Treatments for MCI
- 7.7.1.2. Non-Pharmacologic Interventions
- 7.7.1.3. Lifestyle Modifications for MCI
- 7.7.2. Treatment Algorithm
- 7.7.3. Treatment Guidelines
- 7.7.3.1. American Academy of Neurology (AAN) Guideline on Mild Cognitive Impairment (MCI)
- 7.7.3.2. British Association for Psychopharmacology (BAP) 2006 Guideline
8. Patient Journey
9. Epidemiology and Patient Population
- 9.1. Key Findings
- 9.2. Assumptions and Rationale: 7MM
- 9.2.1. Diagnosed prevalent cases of Parkinson's Disease
- 9.2.2. Diagnosed Prevalent Cases of Alzheimer's Disease
- 9.2.3. Diagnosed Prevalent Cases of MCI
- 9.2.3.1. Diagnosed Prevalent Cases of MCI due to Parkinson's Disease
- 9.2.3.2. Diagnosed Prevalent Cases of MCI due to Alzheimer's Disease
- 9.3. Total Diagnosed Prevalent Cases of MCI in the 7MM
- 9.4. The United States
- 9.4.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in the US
- 9.4.2. Total Diagnosed Prevalent Cases of Alzheimer's Disease in the US
- 9.4.3. Total Diagnosed Prevalent Cases of MCI in the US
- 9.5. EU4 and the UK
- 9.5.1. Germany
- 9.5.1.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in Germany
- 9.5.1.2. Total Diagnosed Prevalent Cases of Alzheimer's Disease in Germany
- 9.5.1.3. Total Diagnosed Prevalent Cases of MCI in Germany
- 9.5.2. France
- 9.5.2.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in France
- 9.5.2.2. Total Diagnosed Prevalent Cases of Alzheimer's Disease in France
- 9.5.2.3. Total Diagnosed Prevalent Cases of MCI in France
- 9.5.3. Italy
- 9.5.3.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in Italy
- 9.5.3.2. Total Diagnosed Prevalent Cases of Alzheimer's Disease in Italy
- 9.5.3.3. Total Diagnosed Prevalent Cases of MCI in Italy
- 9.5.4. Spain
- 9.5.4.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in Spain
- 9.5.4.2. Total Diagnosed Prevalent Cases of Alzheimer's Disease in Spain
- 9.5.4.3. Total Diagnosed Prevalent Cases of MCI in Spain
9.5.5.. The UK
- 9.5.5.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in the UK
- 9.5.5.2. Total Diagnosed Prevalent Cases of Alzheimer's Disease in the UK
- 9.5.5.3. Total Diagnosed Prevalent Cases of MCI in the UK
- 9.6. Japan
- 9.6.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in Japan
- 9.6.2. Total Diagnosed Prevalent Cases of Alzheimer's Disease in Japan
- 9.6.3. Total Diagnosed Prevalent Cases of MCI in Japan
10. Marketed Drugs
- 10.1. Key Cross Competition of Marketed Drugs
- 10.2. LEQEMBI (lecanemab): Biogen Inc./Eisai Co., Ltd.
- 10.2.1. Product Description
- 10.2.2. Regulatory Milestones
- 10.2.3. Other Developmental Activities
- 10.2.4. Clinical Trials Information
- 10.2.5. Safety and Efficacy
- 10.3. KISUNLA (Donanemab): Eli Lilly and Company
- 10.3.1. Product Description
- 10.3.2. Regulatory Milestones
- 10.3.3. Other Developmental Activities
- 10.3.4. Clinical Trials Information
- 10.3.5. Safety and Efficacy
11. Emerging Drug Profiles
- 11.1. Key Cross Competition of Emerging Drugs
- 11.2. Valiltramiprosate (ALZ-801): Alzheon Inc.
- 11.2.1. Product Description
- 11.2.2. Other Developmental Activities
- 11.2.3. Clinical Trials Information
- 11.2.4. Safety and Efficacy
- 11.2.5. Analyst Views
- 11.3. Mirodenafil (AR1001): AriBio Co., Ltd.
- 11.3.1. Product Description
- 11.3.2. Other Developmental Activities
- 11.3.3. Clinical Trials Information
- 11.3.4. Safety and Efficacy
- 11.3.5. Analyst Views
- 11.4. Remternetug (LY3372993): Eli Lilly
- 11.4.1. Product Description
- 11.4.2. Clinical Trial Information
- 11.4.3. Safety and Efficacy
- 11.4.4. Analyst Views
- 11.5. Semaglutide (NN6535): Novo Nordisk
- 11.5.1. Product Description
- 11.5.2. Clinical Trial Information
- 11.5.3. Safety and Efficacy
- 11.5.4. Analyst Views
- 11.6. Levetiracetam (AGB101): AgeneBio, Inc.
- 11.6.1. Product Description
- 11.6.2. Other Developmental Activities
- 11.6.3. Clinical Trials Information
- 11.6.4. Safety and Efficacy
- 11.6.5. Analyst Views
- 11.7. Blarcamesine (ANAVEX2-73): Anavex Life Sciences Corp.
- 11.7.1. Product Description
- 11.7.2. Other Developmental Activities
- 11.7.3. Clinical Trials Information
- 11.7.4. Safety and Efficacy
- 11.7.5. Analyst Views
- 11.8. Hydromethylthionine Mesylate (HMTM)/TRx0237: TauRx Therapeutics
- 11.8.1. Product Description
- 11.8.2. Other Developmental Activity
- 11.8.3. Clinical Trials Information
- 11.8.4. Safety and Efficacy
- 11.8.5. Analyst's Views
- 11.9. ABvac40: Araclon Biotech S.L.
- 11.9.1. Product Description
- 11.9.2. Other Development Activities
- 11.9.3. Clinical Trials Information
- 11.9.4. Safety and Efficacy
- 11.9.5. Analyst Views
- 11.1. ACI-35.030/JNJ-2056 : AC Immune SA/Johnson & Johnson
- 11.10.1. Product Description
- 11.10.2. Other Developmental Activities
- 11.10.3. Clinical Trials Information
- 11.10.4. Safety and Efficacy
- 11.10.5. Analysts' Views
12. Mild Cognitive Impairment (MCI): Market Analysis
- 12.1. Key Findings
- 12.2. Key Market Forecast Assumptions
- 12.3. Market Outlook
- 12.4. Conjoint Analysis
- 12.5. Total Market Size of MCI in the 7MM
- 12.6. Market Size of MCI by Therapies in the 7MM
- 12.7. Market Size of MCI in the United States
- 12.7.1. Total Market Size of MCI
- 12.7.2. Market Size of MCI by Therapies in the United States
- 12.8. Market Size of MCI in EU4 and the UK
- 12.8.1. Market Size of MCI in Germany
- 12.8.1.1. Total Market Size of MCI
- 12.8.1.2. Market Size of MCI by Therapies in Germany
- 12.8.2. Market Size of MCI in France
- 12.8.2.1. Total Market Size of MCI
- 12.8.2.2. Market Size of MCI by Therapies in France
- 12.8.3. Market Size of MCI in Italy
- 12.8.3.1. Total Market Size of MCI
- 12.8.3.2. Market Size of MCI by Therapies in Italy
- 12.8.4. Market Size of MCI in Spain
- 12.8.4.1. Total Market Size of MCI
- 12.8.4.2. Market Size of MCI by Therapies in Spain
- 12.8.5. Market Size of MCI in the UK
- 12.8.5.1. Total Market Size of MCI
- 12.8.5.2. Market Size of MCI by Therapies in the UK
- 12.9. Market Size of MCI in Japan
- 12.9.1. Total Market Size of MCI
- 12.9.2. Market Size of MCI by Therapies in Japan
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
- 16.1. The United States
- 16.1.1. Center for Medicare and Medicaid Services (CMS)
- 16.2. In EU4 and the UK
- 16.2.1. Germany
- 16.2.2. France
- 16.2.3. Italy
- 16.2.4. Spain
- 16.2.5. The United Kingdom
- 16.3. Japan
17. Appendix
- 17.1. Bibliography
- 17.2. Acronyms and Abbreviations
- 17.3. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
